Aker BioMarine Future Growth

Future criteria checks 3/6

Aker BioMarine's revenue is forecast to decline at 6.7% per annum while its annual earnings are expected to grow at 101.6% per year. EPS is expected to grow by 101.3% per annum. Return on equity is forecast to be 8.4% in 3 years.

Key information

101.6%

Earnings growth rate

101.3%

EPS growth rate

Food earnings growth	34.4%
Revenue growth rate	-6.7%
Future return on equity	8.4%
Analyst coverage	Low
Last updated	02 Dec 2024

Recent future growth updates

Recent updates

Aker BioMarine AS' (OB:AKBM) Share Price Boosted 34% But Its Business Prospects Need A Lift Too

Dec 20

Aker BioMarine (OB:AKBM) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of

Nov 08

Aker BioMarine AS' (OB:AKBM) Revenues Are Not Doing Enough For Some Investors

Nov 05

At kr102, Is It Time To Put Aker BioMarine AS (OB:AKBM) On Your Watch List?

Aug 20

Optimistic Investors Push Aker BioMarine AS (OB:AKBM) Shares Up 25% But Growth Is Lacking

Jul 19

What Does The Future Hold For Aker BioMarine AS (OB:AKBM)? These Analysts Have Been Cutting Their Estimates

Jul 16

There Are Reasons To Feel Uneasy About Aker BioMarine's (OB:AKBM) Returns On Capital

Jul 11

These 4 Measures Indicate That Aker BioMarine (OB:AKBM) Is Using Debt In A Risky Way

Jun 03

There's No Escaping Aker BioMarine AS' (OB:AKBM) Muted Revenues

Feb 15

There Are Reasons To Feel Uneasy About Aker BioMarine's (OB:AKBM) Returns On Capital

Nov 06

Estimating The Fair Value Of Aker BioMarine AS (OB:AKBM)

Sep 06

We Think You Should Be Aware Of Some Concerning Factors In Aker BioMarine's (OB:AKBM) Earnings

Nov 04

Aker BioMarine AS' (OB:AKBM) Has Found A Path To Profitability

Apr 13

Aker BioMarine AS (OB:AKBM) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Feb 18

Loss-Making Aker BioMarine AS (OB:AKBM) Set To Breakeven

Jan 07

Earnings and Revenue Growth Forecasts

OB:AKBM - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	271	20	23	33	2
12/31/2025	241	9	9	13	2
12/31/2024	255	1	-18	-3	2
9/30/2024	335	3	14	52	N/A
6/30/2024	338	-11	26	69	N/A
3/31/2024	336	-8	6	51	N/A
12/31/2023	335	-9	-2	47	N/A
9/30/2023	227	-15	-20	25	N/A
6/30/2023	242	0	-41	5	N/A
3/31/2023	268	14	-35	12	N/A
12/31/2022	277	10	-31	15	N/A
9/30/2022	274	1	-43	-2	N/A
6/30/2022	268	10	-27	9	N/A
3/31/2022	269	-8	-29	4	N/A
12/31/2021	262	-8	-78	3	N/A
9/30/2021	262	3	-85	-17	N/A
6/30/2021	270	-8	-139	-63	N/A
3/31/2021	268	-14	-134	-59	N/A
12/31/2020	289	-5	-75	-51	N/A
9/30/2020	285	-26	-65	-23	N/A
6/30/2020	284	-28	-12	19	N/A
3/31/2020	278	-18	-3	33	N/A
12/31/2019	246	-24	-115	12	N/A
12/31/2018	154	-1	-57	8	N/A
12/31/2017	126	-18	N/A	N/A	N/A
9/30/2017	123	-15	N/A	N/A	N/A
6/30/2017	122	-11	N/A	N/A	N/A
3/31/2017	119	-5	N/A	N/A	N/A
12/31/2016	117	-2	N/A	21	N/A
9/30/2016	111	-8	N/A	N/A	N/A
6/30/2016	110	0	N/A	N/A	N/A
3/31/2016	109	-3	N/A	N/A	N/A
12/31/2015	105	1	N/A	18	N/A
9/30/2015	105	-5	N/A	N/A	N/A
6/30/2015	103	-14	N/A	N/A	N/A
3/31/2015	111	-13	N/A	N/A	N/A
12/31/2014	112	-17	N/A	-11	N/A
9/30/2014	99	-34	N/A	N/A	N/A
6/30/2014	109	44	N/A	N/A	N/A
3/31/2014	106	43	N/A	N/A	N/A
12/31/2013	109	47	N/A	N/A	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: AKBM's forecast earnings growth (101.6% per year) is above the savings rate (2.4%).

Earnings vs Market: AKBM's earnings (101.6% per year) are forecast to grow faster than the Norwegian market (9.4% per year).

High Growth Earnings: AKBM's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: AKBM's revenue is expected to decline over the next 3 years (-6.7% per year).

High Growth Revenue: AKBM's revenue is forecast to decline over the next 3 years (-6.7% per year).

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: AKBM's Return on Equity is forecast to be low in 3 years time (8.4%).

Discover growth companies

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2024/12/19 08:01
End of Day Share Price	2024/12/19 00:00
Earnings	2024/09/30
Annual Earnings	2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Aker BioMarine AS is covered by 6 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Kristofer Liljeberg-Svensson	Carnegie Investment Bank AB
Ole-Andreas Krohn	DNB Markets
Ola Trovatn	DNB Markets

Aker BioMarine Future Growth

Future criteria checks 3/6

Key information

Recent future growth updates

Consensus EPS estimates fall by 58%

Consensus EPS estimates increase by 135%

Consensus EPS estimates fall by 17%

Consensus EPS estimates fall by 69%

Aker BioMarine AS Provides Revenue Guidance for the Full Year of 2023

Aker BioMarine AS Provides Revenue Guidance for the Full Year of 2023

Recent updates

Aker BioMarine AS' (OB:AKBM) Share Price Boosted 34% But Its Business Prospects Need A Lift Too

Aker BioMarine AS, Annual General Meeting, Apr 25, 2025

Aker BioMarine AS to Report Q4, 2024 Results on Feb 12, 2025

Director recently bought kr232k worth of stock

Consensus EPS estimates fall by 58%

Consensus EPS estimates increase by 135%

Consensus EPS estimates fall by 17%

Aker BioMarine (OB:AKBM) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of

Aker BioMarine AS' (OB:AKBM) Revenues Are Not Doing Enough For Some Investors

New major risk - Financial position

Third quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

New major risk - Share price stability

Aker BioMarine AS Announces Extraordinary Dividend, Payable on 30 September 2024

At kr102, Is It Time To Put Aker BioMarine AS (OB:AKBM) On Your Watch List?

Optimistic Investors Push Aker BioMarine AS (OB:AKBM) Shares Up 25% But Growth Is Lacking

What Does The Future Hold For Aker BioMarine AS (OB:AKBM)? These Analysts Have Been Cutting Their Estimates

Second quarter 2024 earnings released: US$0.03 loss per share (vs US$0.005 profit in 2Q 2023)

Aker BioMarine AS Expects to Pay Extraordinary Dividend

Aker BioMarine AS Expects to Pay Extraordinary Dividend

There Are Reasons To Feel Uneasy About Aker BioMarine's (OB:AKBM) Returns On Capital

Aker BioMarine Antarctic Holding II AS completed the acquisition of Feed Ingredients business of Aker BioMarine AS (OB:AKBM).

AIP, LLC and Aker Capital ASA agreed to acquire Feed Ingredients business from Aker BioMarine AS (OB:AKBM).

AIP, LLC and Aker Capital ASA agreed to acquire Feed Ingredients business from Aker BioMarine AS (OB:AKBM).

These 4 Measures Indicate That Aker BioMarine (OB:AKBM) Is Using Debt In A Risky Way

First quarter 2024 earnings released: US$0.07 loss per share (vs US$0.20 loss in 1Q 2023)

Consensus EPS estimates fall by 69%

Full year 2023 earnings: EPS exceeds analyst expectations

Full year 2023 earnings released: US$0.10 loss per share (vs US$0.11 profit in FY 2022)

There's No Escaping Aker BioMarine AS' (OB:AKBM) Muted Revenues

There Are Reasons To Feel Uneasy About Aker BioMarine's (OB:AKBM) Returns On Capital

Third quarter 2023 earnings released: US$0.01 loss per share (vs US$0.05 profit in 3Q 2022)

Aker BioMarine AS to Report Q1, 2024 Results on Apr 25, 2024

No independent directors

Aker BioMarine ASA Receives Approval for LYSOVETA as New Dietary Suppient in the US

Aker BioMarine AS Provides Revenue Guidance for the Full Year of 2023

Aker BioMarine AS Provides Revenue Guidance for the Full Year of 2023

Consensus EPS estimates fall from profit to US$0.086 loss, revenue upgraded

Full year 2022 earnings: EPS misses analyst expectations

Consensus EPS estimates increase by 308%

Consensus EPS estimates fall by 65%

Chairman recently bought kr5.4m worth of stock

Full year 2022 earnings: EPS misses analyst expectations

Aker BioMarine ASA Announces Ministry of Food and Drug Safety in South Korea Approves Superba Krill Oil

Chief Executive Officer recently bought kr305k worth of stock

No independent directors

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Consensus forecasts updated

Consensus EPS estimates increase by 57%

Now 20% undervalued

Estimating The Fair Value Of Aker BioMarine AS (OB:AKBM)

Consensus EPS estimates increase by 136%

Consensus forecasts updated

Aker Biomarine as Reiterates Earnings Guidance for the Full Year of 2022

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Aker BioMarine AS Appoints Mr. Øyvind Eriksen as an Observer to the Board on June 8, 2022

Now 20% undervalued

Forecast breakeven date moved forward to 2022

Now 22% undervalued

First quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

No independent directors

Aker Biomarine AS Announces Board Changes

Full year 2021 earnings: EPS and revenues miss analyst expectations

Aker BioMarine AS, Annual General Meeting, Apr 20, 2022

Aker BioMarine AS, Annual General Meeting, Apr 20, 2022

Consensus forecasts updated

Forecast breakeven date moved forward to 2022

Forecast breakeven date moved forward to 2022

Full year 2021 earnings: EPS and revenues miss analyst expectations

Chairman recently bought kr9.4m worth of stock